Ervogastat

N/A

Report date: 2025/12/18 10:33:48
NME

Base Information

Drug NameErvogastat
Drug Alias NamePF-06865571
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDiacylglycerol O-acyltransferase 1 inhibitorsDiacylglycerol O-acyltransferase 2 inhibitors
TargetsDiacylglycerol O-acyltransferase 1Diacylglycerol O-acyltransferase 2
Therapy Area/IndicationsFibrosisLiver CirrhosisHepatic Insufficiency +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncMadrigal Pharmaceuticals IncPfizer Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsFibrosisLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A